Source comparison
CJC-1295 No DAC vs. CJC-1295 with DAC: Comparison
Half-Life ~30 minutes (functional GH pulse duration: 6–8 hours) 6–8 days (sustained GH elevation) No DAC requires multiple weekly doses; DAC allows once-weekly or less frequent dosing GH Secretion Pattern Pulsatile. Mimics endogenous GHRH signaling Sustained.
This comparison does not assign a generated winner or score.
- Half-Life
- ~30 minutes (functional GH pulse duration: 6–8 hours)
- 6–8 days (sustained GH elevation)
- No DAC requires multiple weekly doses; DAC allows once-weekly or less frequent dosing
- GH Secretion Pattern
- Pulsatile. Mimics endogenous GHRH signaling
- Sustained. Continuous low-level GH elevation
- No DAC preserves physiological pulsatility; DAC overrides natural rhythm
- Peak GH Elevation
- 15–30× baseline at 2–4 hours, returns to baseline by 6–8 hours
- 3–5× baseline sustained over days
- No DAC produces higher acute peaks but shorter duration
- IGF-1 Response
- Modest increase (15–20% over 48 hours)
- Significant increase (50–100% sustained over weeks)
- DAC formulations produce more pronounced anabolic signaling
- Dosing Frequency
- 2–3× per week minimum to maintain effect
- Once weekly or every 3–5 days
- No DAC requires more frequent administration for sustained benefit
- Side Effect Profile
- Transient flushing, headache, mild hyperglycemia (resolves within hours)
- Persistent water retention, joint pain, potential insulin resistance with chronic use
- No DAC side effects are self-limiting; DAC effects accumulate
- Clinical Trial Evidence
- Phase I data in healthy adults (Jetté 2005, 2006)
- Phase II data in GH-deficient adults and elderly (Teichman 2006)
- Both have published human safety data, but DAC has more extensive long-term follow-up